Elisabeth Walker
Family · Rocklin, CANPI 1972850360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by GSK at 33.2% of the total. Reporting peaked in 2023 at $437 and has fallen 54.6% since, to $199 in 2025.
Across 85 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$582
- AbbVie$539
- AstraZeneca$98
- Boston Scientific$89
- Astellas Pharma US Inc$75
- Novartis$66
- plus $305 from 12 others
What the payments were for
- Food & beverage$1,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $582 |
| AbbVie | 24 | $539 |
| AstraZeneca | 7 | $98 |
| Boston Scientific | 4 | $89 |
| Astellas Pharma US Inc | 4 | $75 |
| Novartis | 3 | $66 |
| Amgen | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Lilly USA, LLC | 2 | $35 |
| Novo Nordisk | 2 | $33 |
| Abbott | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $5 |
How this compares
$1,754 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,622 |
| Gabapentin | 30 | $866 |
| Levothyroxine Sodium | 46 | $763 |
| Lisinopril | 48 | $471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $451 |
| Metoprolol Succinate | 23 | $415 |
| Atorvastatin Calcium | 35 | $347 |
| Ibuprofen | 34 | $318 |
| Amlodipine Besylate | 35 | $284 |
| Fluoxetine Hcl | 23 | $275 |
| Omeprazole | 34 | $266 |
| Atenolol | 24 | $251 |
| Losartan Potassium | 44 | $248 |
| Ezetimibe | 20 | $224 |
| Pravastatin Sodium | 19 | $222 |
Paid to pharmacies, not to this prescriber.
Other family in Rocklin
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.